@inproceedings{inproceedings, title  = {{Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial}},

 url = {{}},

 year = {{2021}},

 month = {{1}},

 author = {{Paller AS and Weidinger S and Cork MJ and Marcoux D and Katoh N and Zhang H and Rossi AB and Shumel B and Zhang A and Prescilla R and Chao J}},

 volume = {{85}},

 journal = {{JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY}},

 issue = {{3}},

 pages = {{AB141-AB141}},

 note = {{Accessed on 2024/12/22}}}